Agile Therapeutics (NSDQ:AGRX) touted data today from a Phase III trial of its once-weekly, low-dose hormonal contraceptive patch, Twirla.
The study showed that women experienced mean decreases in length of bleeding and spotting episodes, the Princeton, N.J.-based company reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Agile Therapeutics touts late-stage trial for once-weekly contraceptive patch appeared first on MassDevice.
from MassDevice http://ift.tt/2zUMxQx
Cap comentari:
Publica un comentari a l'entrada